BillionToOne is a precision diagnostics company that develops molecular diagnostics using its proprietary Quantitative Counting Templates (QCT) platform to detect and quantify genetic targets at the single-molecule level. The company focuses on prenatal screening through its UNITY prenatal screening tests and liquid biopsy solutions for oncology applications. Its patented smNGS platform achieves single-molecule resolution for detecting disease-related DNA fragments with absolute quantification.
Billion to One is publicly traded
IPO'd on Nov 6, 2025
This company is no longer available on our private secondary market. Shares can be traded publicly under BLLN.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2016
Employees
501–1,000
Total Funding
$528.5M
7 rounds
Last Private Valuation
$1B
Jun 1, 2024
Priced upsized IPO at $60.00/share, raising ~$273.1M gross proceeds, began trading on Nasdaq as BLLN.
Public listing sets a market-clearing price, ending private secondary-market valuation ambiguity.
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $528.5M across 7 rounds
Last updated 09-03-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Aug 2, 2024 | Debt Facility | $140M | — | Oberland Capital |
| Jun 2024 | Series D | $130M | $1B | Premji Invest |
| Dec 15, 2022 | Series C Extension | $48.5M | — | Not disclosed |
Oguzhan Atay
Co-Founder and Chief Executive Officer
David Tsao
Co-Founder and Chief Technology Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Natera
Leading prenatal screening company with Panorama and Horizon tests for genetic risk assessment; dominant player with ~35-40% prenatal screening volume.
Invitae
Genetic testing company offering carrier screening and NIPT tests in the reproductive health and prenatal diagnostics space.
Myriad Genetics
Diagnostic company offering Prequel noninvasive prenatal screening test competing directly with BillionToOne's UNITY tests.
LabCorp
Major clinical laboratory company offering MaterniT21 NIPT prenatal screening test.
Illumina
Genomics sequencing company with VeriSeq NIPT solution and owner of GRAIL for oncology diagnostics.
Quest Diagnostics
Major clinical diagnostic company offering prenatal screening and molecular diagnostic services.
Yes, Billion to One is publicly traded under the ticker symbol BLLN on the Nasdaq. The company went public in Nov 6, 2025.
Billion to One trades under the ticker symbol BLLN on the Nasdaq. It began trading in Nov 6, 2025.
Billion to One (BLLN on the Nasdaq) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker BLLN to place an order.
Billion to One went public in Nov 6, 2025 via ipo, with an offering valuation of approximately $1B. BillionToOne completed its initial public offering on the Nasdaq Global Select Market on November 6, 2025, listing Class A common stock under the ticker BLLN at $60.00 per share, above the marketed range of $49-$55. Including the underwriters' full exercise of their option to purchase additional shares, the company sold 5,233,765 shares for aggregate gross proceeds of approximately $314.0 million. The stock closed its first day of trading at $108.94, about 81.5% above the offering price.
Billion to One raised $528.5M across 7 disclosed funding rounds prior to its public listing.
Billion to One was co-founded by Oguzhan Atay, and David Tsao in 2016.
Billion to One is headquartered in Menlo Park, California.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.